ASCO 2007 - Phase II of AZD2171 in recurrent GBM - Part I
Background: AZD2171 (cediranib) is a potent, oral pan-VEGF receptor tyrosine kinase inhibitor with a half-life of 20 hours compatible with once-daily dosing. A primary target of AZD2171, VEGFR2, is expressed on glioblastoma endothelium. We have demonstrated normalization of tumor vessels in recurrent glioblastoma patients treated with daily doses of AZD2171. Normalization has rapid onset, is reversible and is associated with alleviation of brain edema. Presented at ASCO 2007. Abstract #2001
cediranib AZD2171 glioblastoma glioma brain cancer tumor ASCO